Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.91 – $13.50
84% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.3M | $13.9M | $8.9M | $11.2M | $12.9M | $18.3M | $17.9M | $12.8M |
| Cost of revenue | $7.0M | $7.2M | $3.8M | $4.5M | $6.7M | $9.2M | $8.4M | $6.0M |
| Gross profit | $4.3M | $6.8M | $5.1M | $6.7M | $6.2M | $9.1M | $9.5M | $6.8M |
| Gross margin | 38.0% | 48.6% | 57.1% | 60.0% | 48.1% | 49.7% | 53.1% | 53.5% |
| R&D | $5.8M | $4.6M | $2.5M | $2.7M | $3.6M | $5.0M | $3.9M | $3.0M |
| Operating income | −$27.0M | −$16.6M | −$12.9M | −$13.8M | −$15.6M | −$15.1M | −$10.5M | −$13.3M |
| EBITDA | −$24.9M | −$11.1M | −$15.1M | −$9.1M | −$14.0M | −$13.2M | −$9.5M | −$9.8M |
| Net income | −$27.0M | −$12.1M | −$15.8M | −$9.8M | −$15.1M | −$15.2M | −$11.3M | −$11.7M |
| Net margin | -238.2% | -87.2% | -178.2% | -86.8% | -116.8% | -83.1% | -63.2% | -91.4% |
| EPS (diluted) | -99.19 | -37.96 | -33.13 | -13.20 | -17.45 | -16.44 | -8.43 | -4.91 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19M | $-0.10 | $-0.10–$-0.10 | 1 |
| 2027 | $24M | $-0.06 | $-0.06–$-0.06 | 1 |
| 2028 | $31M | $0.03 | $0.03–$0.03 | 1 |
| 2029 | $38M | $0.14 | $0.14–$0.14 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds EKSO.
No tracked institution reports a position in EKSO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-06-02 | 1-for-15reverse |
| 2020-03-25 | 1-for-15reverse |
| 2016-05-05 | 1-for-7reverse |
No one on the platform has traded EKSO yet.
| $18M |
| — |
| CODXCo-Diagnostics, Inc. | $2.98 | -2.61% | $3M | — |
| ERNAErnexa Therapeutics Inc. | $7.03 | +0.86% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.8× sales vs its 1.4× historical median P/S.
Fair value ≈ $20.77 · price $11.80 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.